Compare Immunovant Inc. Common Stock (IMVT) vs Synchrony Financial (SYF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Immunovant Inc. Common Stock vs Synchrony Financial — how do they compare? Immunovant Inc. Common Stock trades at $30.36 (market cap $6.25B), while Synchrony Financial trades at $72.89 (market cap $23.99B). The key difference: Synchrony Financial is far larger — about 3.8× Immunovant Inc. Common Stock's market cap, and Synchrony Financial pays a 1.84% dividend while Immunovant Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Immunovant Inc. Common Stock for 1 Days and Synchrony Financial for 29 Days on average.
| IMVT | SYF | |
|---|---|---|
Market Cap | $6.25B | $23.99B |
Volume | 1,755,411 | 3,813,027 |
Sector | Health | Financials |
52-Week High | $44.96 | $88.47 |
52-Week Low | $17.03 | $63.78 |
Typical Hold Time | 1 Days | 29 Days |
Enterprise Value | $5.35B | $24.23B |
Dividend Yield | — | 1.84% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Synchrony Financial (SYF) trades at $72.87, up 1.31% with bullish technical signals despite mixed momentum indicators. The stock shows strong fundamentals with a low P/E of 7.56, robust ROE of 22.23%, and consistent earnings beats. Recent partnerships with OpenAI and Vetspire highlight strategic growth initiatives in AI-driven commerce and veterinary financing.
SYF presents compelling value with attractive valuation metrics and strong profitability, though investors face risks from consumer credit quality and competitive pressures. Analyst consensus targets $87.58 (20% upside) with 61% buy ratings, supporting a positive outlook if the company maintains its earnings trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Immunovant Inc. Common Stock
Immunovant is a clinical-stage immunology company developing therapies for autoimmune diseases. Its pipeline includes anti-FcRn antibody candidates designed for subcutaneous administration.
Read more on IMVT →About Synchrony Financial
Synchrony Financial is a premier consumer financial services company and the largest provider of private-label credit cards in the United States. Spun off from GE Capital in 2014, it operates through a unique B2B2C model, embedding its financing products within the ecosystems of major partners like Amazon, Lowe’s, and PayPal. Synchrony leverages deep data analytics and a diverse multi-platform strategy—spanning retail, health, and auto—to drive customer loyalty and provide specialized credit solutions at the point of sale.
Read more on SYF →
